Health Condition 1: K758- Other specified inflammatory liverdiseases
Conditions
Interventions
Intervention1: Muliv Strong Syrup: Muliv Strong Syrup orally 10 ml TDS before meal for 45 days
Control Intervention1: NIL: NIL
Sponsors
Multani Pharmaceuticals Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients of either sex not taking any medicine will be included in the study. 2. Individuals suffering from NAFLD with or without elevated liver enzymes or hepatomegaly will be included. 3. Patients willing to give informed consent for the study.
Exclusion criteria
Exclusion criteria: 1. Individuals with chronic hepatitis (more than 3 months), Patients with malignant jaundice, patient with acute hepatitis (Other than infective). 2. Individuals with known hypersensitivity to ingredients of study products; individuals with immediate life threatening diseases such as preexisting cardiovascular, liver, or neoplastic diseases or who received any immunosuppressant, sedative, hypnotic or tranquilizer within 14 days prior to enrollment; 3. Individuals with any psychiatric illness which may impair the ability to provide written ICF. 4. Individuals participating in any other clinical trial. 5. Pregnant or lactating females. 6. Alcohol, smoke, and drug abusers will be excluded from study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in NAFLD ScoreTimepoint: 60 days | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in Subjective parameters, LFT, USGTimepoint: 60days | — |
Countries
India
Contacts
Public ContactDr Suman Sharma
Multani Pharmaceuticals Ltd.
Outcome results
None listed